A detailed history of Rhumbline Advisers transactions in Codexis, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 104,178 shares of CDXS stock, worth $533,391. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104,178
Previous 108,594 4.07%
Holding current value
$533,391
Previous $336,000 4.76%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.62 - $3.71 $11,569 - $16,383
-4,416 Reduced 4.07%
104,178 $320,000
Q2 2024

Aug 01, 2024

BUY
$2.65 - $3.92 $10,645 - $15,746
4,017 Added 3.84%
108,594 $336,000
Q1 2024

May 09, 2024

BUY
$2.59 - $4.65 $7,365 - $13,224
2,844 Added 2.8%
104,577 $364,000
Q4 2023

Feb 08, 2024

BUY
$1.54 - $3.37 $1,014 - $2,220
659 Added 0.65%
101,733 $310,000
Q3 2023

Nov 09, 2023

BUY
$1.5 - $3.75 $2,289 - $5,722
1,526 Added 1.53%
101,074 $191,000
Q2 2023

Aug 08, 2023

BUY
$2.21 - $4.43 $37,760 - $75,690
17,086 Added 20.72%
99,548 $278,000
Q1 2023

May 11, 2023

BUY
$3.81 - $6.76 $15,217 - $26,999
3,994 Added 5.09%
82,462 $341,000
Q4 2022

Feb 14, 2023

SELL
$4.26 - $6.84 $3,152 - $5,061
-740 Reduced 0.93%
78,468 $366,000
Q3 2022

Nov 10, 2022

BUY
$6.06 - $12.86 $46,110 - $97,851
7,609 Added 10.63%
79,208 $480,000
Q2 2022

Aug 11, 2022

BUY
$8.35 - $21.89 $60,771 - $159,315
7,278 Added 11.32%
71,599 $749,000
Q1 2022

May 12, 2022

BUY
$16.97 - $31.93 $4,157 - $7,822
245 Added 0.38%
64,321 $1.33 Million
Q4 2021

Feb 10, 2022

SELL
$25.61 - $41.78 $18,029 - $29,413
-704 Reduced 1.09%
64,076 $2 Million
Q3 2021

Nov 12, 2021

BUY
$19.65 - $27.99 $51,325 - $73,109
2,612 Added 4.2%
64,780 $1.51 Million
Q2 2021

Aug 05, 2021

SELL
$17.48 - $25.46 $41,934 - $61,078
-2,399 Reduced 3.72%
62,168 $1.41 Million
Q1 2021

May 06, 2021

SELL
$18.08 - $28.8 $84,451 - $134,524
-4,671 Reduced 6.75%
64,567 $1.48 Million
Q4 2020

Feb 10, 2021

BUY
$11.7 - $23.41 $39,791 - $79,617
3,401 Added 5.17%
69,238 $1.51 Million
Q3 2020

Nov 12, 2020

SELL
$11.21 - $13.82 $102,851 - $126,798
-9,175 Reduced 12.23%
65,837 $773,000
Q2 2020

Aug 13, 2020

SELL
$9.8 - $12.77 $117 - $153
-12 Reduced 0.02%
75,012 $855,000
Q1 2020

May 06, 2020

BUY
$8.78 - $18.6 $11,212 - $23,752
1,277 Added 1.73%
75,024 $837,000
Q4 2019

Feb 05, 2020

BUY
$13.12 - $17.06 $54,159 - $70,423
4,128 Added 5.93%
73,747 $1.18 Million
Q3 2019

Oct 23, 2019

SELL
$12.75 - $19.01 $4,513 - $6,729
-354 Reduced 0.51%
69,619 $955,000
Q2 2019

Aug 14, 2019

BUY
$17.0 - $21.88 $48,705 - $62,686
2,865 Added 4.27%
69,973 $1.29 Million
Q1 2019

May 01, 2019

SELL
$15.53 - $22.15 $3,028 - $4,319
-195 Reduced 0.29%
67,108 $1.38 Million
Q4 2018

Jan 31, 2019

BUY
$14.06 - $22.57 $314,704 - $505,184
22,383 Added 49.83%
67,303 $1.12 Million
Q3 2018

Nov 07, 2018

SELL
$13.35 - $19.1 $49,942 - $71,453
-3,741 Reduced 7.69%
44,920 $770,000
Q2 2018

Aug 06, 2018

BUY
$10.35 - $16.45 $113,674 - $180,670
10,983 Added 29.15%
48,661 $701,000
Q1 2018

May 02, 2018

BUY
$8.0 - $12.8 $14,280 - $22,848
1,785 Added 4.97%
37,678 $414,000
Q4 2017

Feb 09, 2018

SELL
$5.85 - $8.4 $44,044 - $63,243
-7,529 Reduced 17.34%
35,893 $300,000
Q3 2017

Nov 06, 2017

BUY
$4.9 - $6.65 $212,767 - $288,756
43,422
43,422 $289,000

Others Institutions Holding CDXS

About CODEXIS, INC.


  • Ticker CDXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,494,100
  • Market Cap $335M
  • Description
  • Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protei...
More about CDXS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.